Personalis, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Personalis, Inc. - overview
Established
2011
Location
Fremont, CA-California, US
Primary Industry
Biotechnology
About
Based in the US, Personalis, Inc. is a biotechnology firm specializing in advanced diagnostics and personalized cancer treatment solutions through innovative genomic analysis. Personalis, Inc. focuses on cancer care, providing diagnostic solutions to detect cancer recurrence.
In July 2026, Tempus AI, Inc. , a portfolio company of Franklin Templeton and SB Investment Advisers, agreed to acquire Majority stake in Personalis, Inc. for USD 1. 5 billion.
with the latest being a Private Placement/Follow on of USD 150. 10 mn in January 2021. Co-founded by Atul Butte, Euan Ashley, and Russ Altman, the company is led by CEO John West. Personalis specializes in advanced cancer diagnostics, with its flagship product, the NeXT Personal®, utilizing ultra-sensitive circulating tumor DNA (ctDNA) analysis to detect cancer recurrence.
This technology enables earlier interventions, especially for early-stage cancers like breast and lung cancers. The company serves oncologists, healthcare institutions, and biopharma partners across North America and Europe, providing crucial information for treatment decisions. In the most recent fiscal year 2024, Personalis reported revenue of USD 84. 61 mn, alongside an EBITDA of USD -68.
27 mn. The company's revenue is derived from its diagnostic testing services, primarily the NeXT Personal® assay, which operates through service agreements with healthcare providers and biopharmaceutical firms. Looking ahead, Personalis aims to expand its operations through new product launches and market penetration. In July 2026, Tempus AI, Inc.
, a portfolio company of Franklin Templeton and SB Investment Advisers, agreed to acquire Personalis, Inc. for USD 1. 5 billion.
Current Investors
Abingworth, Lightspeed Venture Partners, Mohr Davidow Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Bioinformatics, Diagnostic, Medical & Imaging Laboratories, Healthcare IT, Analytics & Performance Software, Medical Software, Scientific Software
Website
www.personalis.com
Verticals
HealthTech
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Personalis, Inc. - timeline of key events
Personalis, Inc. - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 9,400,000 | 37,800,000 | 65,207,000 | 78,648,000 | 85,494,000 | 65,047,000 | - | - | - |
| % Revenue Growth (YoY) | - | 302.1% | 72.5% | 20.6% | 8.7% | (23.9%) | - | - | - |
| EBITDA (USD) | (21,200,000) | (15,200,000) | (17,670,000) | (35,997,000) | (57,308,000) | (107,042,000) | - | - | - |
| Operating Income (USD) | (22,400,000) | (18,300,000) | (22,418,000) | (42,146,000) | (65,353,000) | (115,531,000) | - | - | - |
| Operating Margin | (238.3%) | (48.4%) | (34.4%) | (53.6%) | (76.4%) | (177.6%) | - | - | - |
| % EBITDA Margin | (225.5%) | (40.2%) | (27.1%) | (45.8%) | (67.0%) | (164.6%) | - | - | - |
| NET Income (USD) | (23,600,000) | (19,900,000) | (25,084,000) | (41,280,000) | (65,226,000) | (113,315,000) | - | - | - |
| % Net Margin | (251.1%) | (52.6%) | (38.5%) | (52.5%) | (76.3%) | (174.2%) | - | - | - |
Personalis, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Announced | Personalis, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Personalis, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Personalis, Inc. | - | ||||||||
| IPO | Completed | Personalis, Inc. | - | ||||||||
| Series C | Completed | Personalis, Inc. | - |
Displaying 1 - 5 of 7
Personalis, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.